TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03054298

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: huCART-meso cells
Description: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: huCART-meso cells
Description: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: huCART-meso cells
Description: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: huCART-meso cells
Description: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..
Study: NCT02012192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study: NCT01420432

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord-derived MSCs
Description: 1.0E+6 MSC/kg, IV drop and repeat repeated after three months
Study: NCT03117283

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach
Description: Patients with advanced posterior gastric wall cancer including in the laparoscopic total gastrectomy (LTG) with bursectomy group will undergo laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laparoscopic D2 radical total gastrectomy without bursectomy
Description: Patients who are included in the laparoscopic total gastrectomy (LTG) without bursectomy group will undergo laparoscopic D2 radical total gastrectomy without bursectomy in a conventional manner.
Study: NCT03054298

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: huCART-meso cells
Description: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: huCART-meso cells
Description: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..
Study: NCT04409548

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: All of the spatial and Temporal Gait parameters

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: All of the spatial and Temporal Gait parameters

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: All of the spatial and Temporal Gait parameters
Study: NCT03054298

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: huCART-meso cells
Description: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..
Study: NCT02058784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pracinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pracinostat
Study: NCT01161472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mg fesoterodine
Description: 4mg tablet once daily for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8mg fesoterodine
Description: 4mg tablet once daily for 3 days followed by 8mg tablet once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam 1mg
Description: 1mg tablet once on last day of treatment period at clinic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet for fesoterodine once daily for 6 days and placebo tablet for alprazolam once on last day of treatment period at clinic
Study: NCT01619332

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEZ763
Description: LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner
Study: NCT00462254

Intervention type: DRUG
Group type: OTHER
Intervention: ROZEREM
Description: 8 mg tablet orally 30 minutes before bedtime for 8 days (Days 4-11).

Intervention type: DRUG
Group type: OTHER
Intervention: Ramelteon
Description: 8 mg tablet orally 30 minutes before bedtime for 8 days (Days 15-22).
Study: NCT02581332

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Meditation Training
Description: Training will be held in groups of up to five participants. All of the participants within this group will receive up to 6 days (20m/d) of meditation training to be administered over 15 days. This is a paradigm similar to one employed in previous studies.
Study: NCT05011825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pregnant Moms' Empowerment Program
Description: The first session introduces women to the group, seeks to build an alliance and sense of group cohesion, and provides safety planning. The second session addresses intergenerational patterns of violence and how such violence contributes to psychopathology in both the prenatal and postnatal period, focusing on violence prevention. Information regarding cognitive restructuring, behavioral activation, and coping styles is provided in session three, as well as the role of healthy relationships and social supports in promoting resilience. This session begins with discussion on health in pregnancy, labor/delivery, and coordinating care across providers. This session also provides psychoeducation related to post-delivery parenting, including infant safety, care and breastfeeding. In the final session, group leaders assist mothers with identification, sensitivity, and responsiveness to infant cues.
Study: NCT02336919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Txt2Prevent
Description: A 60-day text messaging program called Txt2Prevent (see description in the arm description).
Study: NCT02596763

Intervention type: DRUG
Group type: OTHER
Intervention: Baclofen
Description: Patient receiving an off-label baclofen treatment for alcohol use disorder for less than 1 month.
Study: NCT04438902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib mesylate tablets and anlotinib hydrochloride capsules
Description: osimertinib mesylate tablets 80mg qd and anlotinib hydrochloride capsules 10mg qd day 1-14 of a 21-day cycle
Study: NCT04220814

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI
Description: MRI protocol is different, a little bit longer than MRI in routine for patients. For healthy volunteer, a specific MRI for this study is done

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI protocol is different, a little bit longer than MRI in routine for patients. For healthy volunteer, a specific MRI for this study is done

Intervention type: OTHER
Group type: OTHER
Intervention: Electrophysiology
Description: Electrophysiology will be done during routine visits for patients and during inclusion visit to healthy volunteers
Study: NCT01520558

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNDO-109-AANK Cells
Description: Single dose, infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNDO-109-AANK Cells
Description: Single dose, infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNDO-109-AANK Cells
Description: Single dose, infusion
Study: NCT01826565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotational technique
Description: 90 degree rotation
Study: NCT00896181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo 3-dimensional conformal or intensity-modulated radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo 3-dimensional conformal or intensity-modulated radiotherapy
Study: NCT01062243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Injury Education
Description: The Brain Injury Inpatient Guide for Families and Caregivers (BIIG-FACS), developed by J. Niemeier and J. Kreutzer, is a comprehensive intervention to meet the needs of family members and significant others of patients who are undergoing acute brain injury rehabilitation.
Study: NCT01704651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan
Description: Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Perioperative administration of placebo, at same dosing interval as study drug.
Study: NCT04082117

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational video
Description: Educational genetic counseling video
Study: NCT02845960

Intervention type: BEHAVIORAL
Intervention: rapid recovery
Description: rapid recovery
Study: NCT04411277

Intervention type: DEVICE
Intervention: Application of the FreeStyle Libre Flash Glucose CGM.
Description: Assessment of glycemic control and hypoglycemia, adherence to therapy and CGM use.

Intervention type: DIAGNOSTIC_TEST
Intervention: InBody 270 multifrequency bioimpedance
Description: analysis of body composition to calculate appendicular skeletal muscle.
Study: NCT03373994

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-FDG PET/CT initial-time imaging
Description: 18F-FDG intravenous bolus injection after a fasting perid of more than 6 hours, simultaneously,PET/CT imaging using one bed lasting 5 minutes was underwent.

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-FDG PET/CT balanced-time imaging
Description: 18F-FDG intravenous injection after a fasting perid of more than 6 hours. After 60 minutes, PET/CT imaging using 6-7 bed positions each lasting 2 minutes was underwent.
Study: NCT02358109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: The exercise intervention will be performed in groups of 20 participants which will train 3 days/week (60 min per session) for a 16-week period. Sessions will be designed and carefully supervised by exercise monitors, including a 15 minute warm-up period followed by 35 minute focused on aerobic exercises, developed progressively at intensity sufficient to achieve 50% (at the beginning of the intervention) and 80% (the last month of the intervention) of predicted maximum heart rate (209-0.73 × age) and resistance strength training.Monday sessions will involve resistance strength exercises. Wednesday sessions will include balance oriented activities and dancing aerobic exercises. Fridays will include aerobic, resistance strength and coordination using a circuit of different exercises.Sessions finish with a 10 minute cool-down period of stretching and relaxation exercises.
Study: NCT01486901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isophane human insulin
Description: Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isophane human insulin
Description: Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
Study: NCT03603730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: Active or inactive taVNS delivered to the external ear at a moderate, non-painful level.
Study: NCT04391738

Intervention type: OTHER
Intervention: Patients admitted to Intensive Care Unit with SARS-CoV2
Description: Patients admitted to Intensive Care Unit with SARS-CoV2
Study: NCT03197324

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexagliflozin
Description: Bexagliflozin tablets, 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: 2 0.25 mg Digoxin tablets (total dose 0.5 mg digoxin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: 2 0.25 mg Digoxin tablets (total dose 0.5 mg digoxin)
Study: NCT02114450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot-assisted training with the H2 lower limb powered exoskeleton
Description: The H2 is a powered, robotic lower limb exoskeleton with actuated hips, knees and ankles. A custom control algorithm has been implemented in this device, which allows for provision of assistance to lower limb segments during movement, dependent on user needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised motor practice
Description: Supervised motor practice involves lower limb rehabilitation, primarily walking and other applicable lower limb exercises performed by participants under the guidance and supervision of a research physical therapist.
Study: NCT04220814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrophysiology
Description: Electrophysiology will be done during routine visits for patients and during inclusion visit to healthy volunteers
Study: NCT01833312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: In patients randomised to therapeutic hypothermia, induction of cooling will be started by infusion of 4°C isotone saline or Ringer's lactate administered over a period of 30 to 60 minutes. A body temperature between 34.0 and 35.0°C will be targeted. Body temperature will be monitored through bladder or rectal thermal probes, and cooling procedures will be adapted to keep body temperature as close as possible to the target. Maintenance of body temperature in the target range will be performed with a surface or endovascular cooling device. After a cooling period of 24h, controlled rewarming to 36°C with a rate of 0.2°C/h will be started. After 36°C have been reached, the device will be disconnected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: anti-shivering treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pethidine
Description: anti-shivering treatment
Study: NCT02489266

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AKTi-treated TIL
Description: On day 0, cells will be infused intravenously (IV) over 20-30 minutes (between 1 and 4 days after the last dose of fludarabine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Patients will receive Fludarabine 25 mg/m2/day for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
Study: NCT01213108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Örebro prevention program
Description: 6 presentations on alcohol-specific parenting practices to parents of 13-16 year olds youth

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Business as usual
Description: Regular alcohol prevention activities and curricula in Swedish schools
Study: NCT00804492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Description: consulted, educated, referred or receive an exercise training for their fitness, strength and balance
Study: NCT04631484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid)
Description: 20 ml (2 ampoules, 10 ml each) dissolved in 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 ml of 0.9% sodium chloride (2 ampoules of 10 ml each), added to 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days
Study: NCT00984321

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: group intervention and questionnaires
Description: Group Session will be 90 minutes long. Both the group sessions and individual session will be audio recorded. GSPI is a novel, manualized psychoeducational intervention that integrates Folkman's cognitive construct and Erikson's developmental concept of the 7th and 8th stages of life. GSPI consist of 5 weekly sessions. The first 2 sessions will be held on consecutive weeks to help establish rapport and explain therapeutic concepts, and next 3 sessions will be held every other week, giving patients time to utilize the therapeutic concepts and expanding length of contact with the patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individual phone intervention and questionnaires
Description: Individual phone sessions will be 45 minutes long. Both the group sessions and individual session will be audio recorded. GSPI is a novel, manualized psychoeducational intervention that integrates Folkman's cognitive construct and Erikson's developmental concept of the 7th and 8th stages of life. GSPI consist of 5 weekly sessions. The first 2 sessions will be held on consecutive weeks to help establish rapport and explain therapeutic concepts, and next 3 sessions will be held every other week, giving patients time to utilize the therapeutic concepts and expanding length of contact with the patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: expressive writing (arm will not be include in the randomization)
Description: intervention facilitate reappraisal through the exploration of past life events and prior successful ways of coping. Preliminary studies examining the efficacy of this writing intervention have shown its' ability to introduce patients to a new and effective coping method that can be utilized during future stressful cancer and aging related events.67 In the sessions, Wwe will explore past life events and ways of coping through manualized writing sessions.
Study: NCT03114202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intensive nutritional counseling
Description: Individualised nutrition intervention in the form of regular and intensive nutrition counselling by a dietitian, following a predetermined standard nutrition protocol, the Medical Nutrition Therapy (Cancer/Radiation Oncology) protocol of the American Dietetic Association (ADA) every week during radiotherapy. Individually tailored sample meal plans, recipe suggestions and hints to minimise the side effects of the tumour and therapy will be provided.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Nutritional counseling / education performed by hospital nurses and nutritional care performed by the hospital nutritionist.
Study: NCT03221088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jintrolong® low dose group
Description: PEG-somatropin 0.1mg/kg/wk by weekly subcutaneous injection for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jintrolong® low dose group
Description: PEG-somatropin 0.1mg/kg/wk by weekly subcutaneous injection for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jintrolong® high dose group
Description: PEG-somatropin 0.2 mg/kg/wk by weekly subcutaneous injection for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jintrolong® high dose group
Description: PEG-somatropin 0.2 mg/kg/wk by weekly subcutaneous injection for 52 weeks.
Study: NCT01611584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA-induced Fluorescence
Description: ALA Dose- 20 mg/kg
Study: NCT02415777

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ursodeoxycholic acid, thiamine, riboflavin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid, thiamine, riboflavin
Study: NCT03595501

Intervention type: DEVICE
Intervention: Hematology Analyzer - OLO
Description: Complete blood counts from OLO will be determined from analysis of whole blood samples

Intervention type: DEVICE
Intervention: Hematology Analyzer - Predicate
Description: Complete blood counts from Predicate will be determined from analysis of whole blood samples
Study: NCT01860443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telepsychiatry collaborative program
Description: The intervention includes:~* Online training for the health staff~* Medical and psychological treatment, as described in the AUGE Clinical Guidelines for Depression~* Online supervision in a web platform by specialists~* Telephone monitoring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: * Online training for the health staff~* Medical and psychological treatment, as described in the AUGE Clinical Guidelines for Depression
Study: NCT01175148

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin calcium (Lipitor)
Description: 40 mg PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin calcium (Lipitor)
Description: 40 mg PO daily
Study: NCT02880007

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: 45 Gy pelvis / 25 fr

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PDR Brachytherapy
Description: 1 puls/hour ; 12 Gy / day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: increase in dose to the target volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume (60 Gy to 90 % of its volume) in 3D Pulsed Dose Rate Brachytherapy
Study: NCT04228640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMN
Description: Investigational Product

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch Powder
Study: NCT03467867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered as described in the reporting arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab (IV) will be administered as described in the reporting arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab/Hyaluronidase Human
Description: Rituximab/Hyaluronidase Human (SC) ill be administered as described in the reporting arm.